Want to see CRBP full AI Analyst Report?
Corbus Pharmaceuticals (CRBP) Income Statement
Corbus Pharmaceuticals Income Statement
Last quarter (Q2 2026), Corbus Pharmaceuticals's total revenue was $0.00. In Q2, Corbus Pharmaceuticals's net income was $-35.04M. See Corbus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 881.71K | |
| $ 0.00 | $ -600.00K | $ 0.00 | $ -1.49M | $ -757.53K | |
| $ 85.31M | $ 48.12M | $ 45.08M | $ 33.35M | $ 55.23M | |
| Depreciation and Amortization | $ 233.00K | $ 588.00K | $ 641.00K | $ 1.49M | $ 1.64M |
| $ -78.30M | $ -37.75M | $ -40.10M | $ -38.73M | $ -42.17M | |
| $ -85.31M | $ -48.72M | $ -45.08M | $ -34.84M | $ -55.99M | |
| $ 6.77M | $ 8.51M | $ 474.00K | $ -7.51M | $ 10.35M | |
| $ -78.54M | $ -40.21M | $ -44.60M | $ -42.35M | $ -45.64M | |
| $ -78.54M | $ -40.21M | $ -44.60M | $ -55.83M | $ -45.55M | |
| Per Share Metrics | |||||
| Basic EPS | $ -5.90 | $ -3.68 | $ -10.31 | $ -10.15 | $ -11.13 |
| Diluted EPS | $ -5.90 | $ -3.68 | $ -10.31 | $ -10.15 | $ -11.13 |
| Weighted Average Shares Outstanding | 13.32M | 10.91M | 4.33M | 4.17M | 4.10M |
| Weighted Average Shares Outstanding (Diluted) | 13.32M | 10.91M | 4.33M | 4.17M | 4.10M |
Currency in USD